OBJECTIVE: Restrictive mitral annuloplasty (RMA) can often improve heart failure symptoms and induce left ventricular (LV) reverse remodelling in patients with non-ischaemic dilated cardiomyopathy (DCM) and functional mitral regurgitation. However, it is unknown whether the observed LV reverse remodelling translates into better outcomes or not.
INTRODUCTION
Functional mitral regurgitation (MR) is frequently observed in patients with advanced dilated cardiomyopathy (DCM) and promotes further left ventricular (LV) remodelling process (MR begets MR) [1] . This condition results in further heart failure progress and is associated with a high morbidity and mortality when treated conservatively, even when mild in dysfunctional LV [2] . To resolve this vicious cycle, Bolling et al. [3] have initially reported the feasibility of mitral annuloplasty in terms of LV reverse remodelling and early and survival benefit. Subsequently, several studies showed that undersized or restrictive mitral annuloplasty (RMA) improved heart failure symptoms and induced a certain degree of LV reverse remodelling [4] [5] [6] [7] [8] . However, there is still a concern whether the observed reverse remodelling is clinically relevant particularly in patients with non-ischaemic DCM, because most studies of this procedure analysed outcomes in ischaemic aetiology [4, 8] or in combined populations of ischaemic and non-ischaemic aetiology [3, 5, 7] . Moreover, because of different pathophysiologic picture and the most important bias of additional surgical procedure (with or without revascularization), the benefit of surgery for non-ischaemic DCM could somewhat be different from ischaemic patients. Therefore, in this study, we examined mid-term outcomes in non-ischaemic DCM focusing on the relationship between the LV reverse remodelling and clinical outcomes after RMA.
PATIENTS AND METHODS

Patients
The study group consisted of 50 DCM patients (37 men and 13 women, mean age 64 ± 10 years) who underwent RMA between April 2005 and December 2009. Patients having LV systolic dysfunction with LV ejection fraction (EF) <35%, 3+ to 4+ functional MR caused by both annular dilatation and systolic restrictive motion of mitral leaflets (Carpentier classification I + IIIb), and congestive heart failure (CHF) symptoms were included in this study. These patients had been prescribed optimal medical therapy before consideration for surgical intervention. All enrolled patients had non-ischaemic aetiology. Therefore, patients who had any history of ischaemic heart disease were excluded in this study. Patients with organic mitral valve disease, significant aortic insufficiency and significant MR preceded cardiomyopathy were also excluded. Table 1 shows preoperative clinical profile of all patients. The institutional ethics committee approved this study and waived individual consent for this retrospective analysis.
Surgical procedures
All operations were performed with conventional cardiopulmonary bypass with mild hypothermia. Myocardial protection was achieved by both antegrade and retrograde cold blood cardioplegia. During this study period, all patients underwent a stringent RMA with the implantation of semi-rigid complete ring (Carpentier Edwards Physio ring; Edward Lifesciences, Irvine, CA, USA). The size of annuloplasty ring used was 24 mm in 28 patients (56%) and 26 mm in 22 patients (44%). Simultaneous procedure included tricuspid annuloplasty in 36 patients (72%), maze procedure in 22 patients (44%) and pulmonary vein isolation for paroxysmal atrial fibrillation in 5 patients (10%). Mean cardiopulmonary bypass and cross-clamping time were 152 ± 50 and 87 ± 36 min, respectively.
Assessment of left ventricular function and degree of mitral regurgitation
Standard trans-thoracic echocardiography was performed to assess LV function pre-and postoperatively. The LV end-diastolic volume (LVEDV), LV end-systolic volume (LVESVI) and LVEF were assessed by the biplane Simpson's equation in apical four-and two-chamber views. The LVEDVI and LVESVI were indexed by the body surface area (LVEDVI and LVESVI, respectively). The LV end-diastolic (LVEDD) and end-systolic dimensions (LVESD), fractional shortening and left atrial diameter were also measured routinely. The severity of MR was graded as 0 (absent), 1+ (mild), 2+ (moderate), 3+ (moderate to severe) and 4+ (severe) on the basis of colour Doppler extent and spatial distribution of the regurgitant jet relative to left atrial area [9] . To assess the mitral valve geometry, the annular septal-lateral diameter was measured as the distance between the septal and lateral mitral annulus in the long-axis view at end-systole. The tenting height was measured as the perpendicular distance between the coaptation point of the mitral leaflets and the line connecting the annular hinge points in the long-axis view at end-systole [10] . To assess the degree of early reverse remodelling, LV functional measurements were performed preoperatively and repeated at 1 month after the operation in all patients. None of the patients underwent the implantation of cardiac support device such as cardiac resynchronization therapy, which can induce LV reverse remodelling by itself [11] , within 1 month after the operation. The available late echocardiographic data at 1 year after surgery were collected in 34 (68%) patients.
Follow-up and assessment of adverse events
After surgery, the patients were kept on standard heart failure medications, including angiotensin-converting enzyme inhibitors or angiotensin-II receptor blockers, β-blockers and diuretics. Follow-up was completed in all patients (100%) by a telephone interview or by a review of the clinical record. The primary adverse events after surgery were defined as cardiac-related death and recurrence of CHF. The diagnosis of postoperative CHF was based on clinical symptoms, physical signs or radiological evidence of pulmonary congestion.
Statistical analysis
The SPSS (version 11.0, SPSS Inc., Chicago, IL, USA) software was used for statistical analysis. The quantitative data are presented as mean ± standard deviation. Continuous variables were expressed as mean ± standard deviation and compared using non-parametric test for paired and unpaired data. Correlation between variables was tested with Pearson's correlation analysis. Calculation of survival and freedom from adverse events was performed by the Kaplan-Meier method and log-rank testing was performed to compare the groups. To clarify the independent predictor, for pre-and intra-operative variables with a P-value <0.1 by univariate comparisons, multivariate logistic regression analysis was performed. The optimal cut-off value was determined by the ROC curve analysis. Statistical significance was defined as P < 0.05.
RESULTS
Early and mid-term clinical outcomes
There was no 30-day mortality. The hospital mortality due to refractory heart failure was noted in four patients (8%). All of them required preoperative inotrops and/or intra-aortic balloon pumping support due to the profound heart failure. The other patients could be discharged with a significant improvement in clinical symptoms. Forty of 46 early survivors (87%) were in NYHA functional class I or II at discharge. During a mean follow-up of 2 years, 12 patients recurred CHF. Of whom, three patients died of progressive heart failure and subsequent multi-organ failure. One patient underwent LV-assisted device implantation at 2 years after surgery and has been waiting for heart transplantation. Overall, the actuarial survival rate at 1 year and 3 years were 85.2 and 85.2%, respectively. Freedom from recurrent heart failure rate at 1 year and 3 years were 76.8 and 64.9%, respectively. Logistic regression analysis was performed to elucidate the predictor for adverse events after surgery (Table 2) . By univariate comparison, possible predictors elucidated were preoperative use of inotrops (P = 0.02), previous cardiac resynchronized therapy (P = 0.09), LVEDVI (P = 0.08), LVESVI (P = 0.04), LVEF (P = 0.01), LVEDD (P = 0.04), LVESD (P = 0.02) and fractional shortening (P = 0.001). Subsequent multivariate analysis demonstrated that the preoperative use of inotrops was the only statistically significant predictor for adverse outcomes (P = 0.04; odds ratio, 8.91; 95% confidence interval, 1.10-78.6).
Early left ventricular reverse remodelling
Significant improvements in LV function accompanied with significant improvements of the MR grade and mitral valve geometry were observed at 1 month after the operation (Table 3) . Both LVEDVI and LVESVI decreased significantly by 14 and 18%, respectively. The extent of reduction was individually varied from −59 to +23% in LVEDVI and −73 to +43% in LVESVI, respectively.
Early left ventricular reverse remodelling and its impact on mid-term outcomes
Based on ROC curve analysis, a reduction in LVESVI of 8.3% was identified as the cut-off value with a sensitivity of 80% and specificity of 78% to predict adverse outcomes after surgery (area under the curve 0.81, P = 0.001). Similarly, a reduction in LVEDVI of 13.8% had a sensitivity and specificity of 87% and 60%, respectively (area under the curve 0.72; P = 0.01). The change in LVESVI was consistently better than the change in LVEDVI in predicting the adverse outcome (Fig. 1) . When the early reduction in LVESVI of ≥9% was used as the cut-off value to define patients with clinical responders, there were 30 (60%) responders and 20 (40%) non-responders. Table 4 demonstrated baseline and postoperative echocardigraphic parameters in each group. Non-responders had more extensive LV remodelling accompanied by significantly depressed systolic function, preoperatively. These trends had been consistently observed in the early and late study periods. A percentage reduction from baseline in LVESVI was progressive in responders but not in non-responders (Fig. 2) . The mean reduction in LVESVI at later period was significantly different between responders and non-responders (41 versus 3.8%, P = 0.002).
The actuarial survival rate at 3 years was significantly better in responders than in non-responders (96.4 versus 68.7%, P = 0.007). Furthermore, responders had significantly better freedom from heart failure rate (85.4 versus 31.8% at 3-year, P = 0.0003) than the non-responders had (Fig. 3) .
Early left ventricular reverse remodelling and mitral regurgitation recurrence
Non-responders had slightly longer tenting height than responders preoperatively; however, the difference was not statistically significant (9.4 ± 3.2 versus 8.4 ± 2.6, P = 0.3). The septo-lateral annular diameter was similar between the groups. At early postoperative study, the mean degree of MR was <1.0 in both the groups (Table 4) . However, the postoperative tenting height was significantly longer in non-responders (7.9 ± 1.3 versus 4.3 ± 2.7, P = 0.03). A linear correlation was noted between the percentage reduction of LVESVI and postoperative tenting height (r = 0.63, P = 0.002), suggesting that the degree of early LV reverse remodelling was related to the improvement of leaflet tethering. At a 1-year follow-up, although no patients had 4+ MR, the incidence of residual MR 2+ or 3+ was higher in nonresponders than in responders (50 versus 27%). The mean grade of MR was significantly greater in non-responders than in responders (P = 0.02).
DISCUSSION
This study examined the relationship between the extent of LV reverse remodelling and mid-term outcomes after RMA in patients with non-ischaemic DCM. Major finding of this study was that the extent of early reduction in LVESVI was related to mid-term mortality, heart failure events, degree of late reverse remodelling and repair durability.
There have been scarce evidences demonstrating the clinical outcomes of mitral valve surgery focusing on non-ischaemic functional MR. Horii et al. [12] reported their results of 46 patients undergoing either mitral repair or replacement. The hospital mortality was 4.3% and the 3-year survival rate was 58.2% in elective cases. Chen et al. [13] demonstrated hospital mortality of 2.4% and a 3-year survival of 79.2% in 42 patients undergoing RMA. The comprehensive analysis from Acker et al. [5] reported the outcome of 193 patients, of whom 61% were idiopathic DCM, undergoing mitral valve surgery with and without the CorCap device. The reported mortality rate, at 30 days, of 1.6% was low and the 2-year survival of 85.2% was acceptable [5] . Our early and mid-term results were comparable with those reports despite a challenging population. Favourable clinical outcomes accompanied with significant LV reverse remodelling were obtained except preoperative inotrops dependents.
There are accumulating evidences that significant LV reverse remodelling has been demonstrated after surgical elimination of functional MR in the failing ventricle. The observed incidence of significant reverse remodelling varied from 41 to 72% [6] [7] [8] . These varied results reflect the differences in patient's characteristics (aetiology, severity), the type of surgical procedures added (revascularization, type of annuloplasty ring used) and the definition of significant LV remodelling (degree of reduction in LV volume or dimension and timing of LV functional assessment). Particularly, these studies mostly included ischaemic functional MR; therefore, the effect of simultaneous revascularization on LV functional recovery should be taken into account. Indeed, De Bonis et al. [7] who studied patients with both ischaemic (n = 51) and non-ischaemic (n = 28) DCM showed that concomitant coronary artery bypass grafting was a statistically significant MR grade 3.6 ± 0.5 3.7 ± 0.5 0.7 ± 0.8 0.8 ± 0.9 0.9 ± 0.8
140 ± 40 165 ± 63 108 ± 37 160 ± 52* 109 ± 45 160 ± 41* LVESVI (ml/m 2 ) 101 ± 37 128 ± 56* 70 ± 39 130 ± 50* 61 ± 47 127 ± 42* LVEF (%) 28 ± 7.6 23 ± 9.1* 37 ± 15 20 ± 8.4* 44 ± 13 24 ± 9.0* LVEDD (mm) 68 ± 8.0 74 ± 11 61 ± 9.3 70 ± 9.7* 59 ± 9.1 69 ± 9.5* LVESD (mm) 57 ± 9.2 66 ± 12* 50 ± 11 64 ± 10* 45 ± 14 62 ± 10* LADs (mm) 50 ± 8.2 50 ± 9.9 44 ± 7.5 44 ± 8.4 48 ± 7.7 46 ± 11 FS (%) 16 ± 6.1 10 ± 4.9* 18 ± 9.2 8.4 ± 3.8* 25 ± 12 10 ± 5.3* R, responder; NR, non-responder *P < 0.05 versus R. predictor of reverse remodelling after mitral repair. Moreover, non-ischaemic DCM is a progressive ventricular disease and the mechanism accounting for functional MR can be different from the ischaemic one [14] . In our study, significant LV reverse remodelling (18% reduction in LVESVI) was found at an early stage after RMA and the early reduction in LVESVI of ≥9% was clinically relevant extent of reverse remodelling. Unfortunately, in our population, early LV reverse remodelling did not occur in a significant number of patients (40%). These early non-responders also showed the lack of late reverse remodelling. Although some previous studies indicated that LV reverse remodelling is a gradual and time-dependent process [5-8, 12, 13] , our study suggested that the LV response in a direction towards either progressive LV reverse remodelling (clinical responders) or persistent LV remodelling (clinical non-responders) had already become obvious at an early stage after surgery. Indeed, we previously reported that the sequence of LV reverse remodelling process occurred at an early stage after RMA [15] . There are still concerns regarding late MR recurrence after ring annuloplasty for functional MR. In our series, despite the successful initial repair, relatively higher incidence of late 2+ MR was observed in the non-responders group (Table 4 ). Our study showed that the degree of LV reverse remodelling was related to the improvement of leaflet tethering. Therefore, non-responders had greater degree of residual leaflet tethering resulted from persistent LV remodelling. That might be a leading cause of greater degree of late MR in non-responders. These results are likely to be attributed to the mechanisms of functional MR itself, which is essentially related to ventricular problem [14] . Although the ring annuloplasty can reduce tethering at the annular end, its ability to compensate for ventricular tethering can be overwhelmed by continued LV remodelling [16] .
To date, a question regarding LV reverse remodelling viability remains unresolved particularly in non-ischaemic DCM patients. In our study, non-responders had more extensive LV remodelling (average LVESVI 128 ml/m 2 ) with depressed systolic function. Not surprisingly, non-responders had worse mid-term survival and functional outcome (Fig. 3) . Previously, we observed that preoperative LVESVI >100 ml/m 2 had a useful marker to predict outcomes in patients undergoing mitral valve replacement for organic MR [17] . Horii et al. [12] also reported that mitral valve surgery did not suffice for extremely dilated LV ( preoperative LVESVI >150 ml/m 2 ) in terms of survival and LV functional improvements. These results imply that the beneficial effects of RMA on LV performance are not enough to overcome the intrinsic LV failure in non-ischaemic DCM patients with extensive remodelling. Moreover, DCM is a progressive ventricular disease. Recent studies including ours have implied that the resolution of annular problem by RMA could provide, at least, less of a stimulus for ongoing pathological remodelling process, but could not restore normal LV function and configuration as seen in the nonfailing hearts. Therefore, more comprehensive reparative correction such as RMA with CorCap device should be required to improve the long-term results [5, 18, 19] . We currently lack sophisticated markers to estimate LV reverse remodelling viability precisely and easily. Our result also suggested that evaluation of the temporary volumetric response could provide complementary information to predict late reverse remodelling viability and clinical outcomes in a series of patients with severe DCM.
LIMITATIONS
There are several limitations in this study. Patient's cohort is relatively small and selection bias is possible. Added surgical procedures such as tricuspid annuloplasty and maze procedure may influence the outcomes. However, current therapies for heart failure patients usually require combination of a number of surgical interventions and medical treatments. Therefore, we think that it is difficult to exclusively investigate the effect of each therapy in the clinical setting. Although the extent of early LV reverse remodelling was clinically meaningful, generalized preoperative marker to identify the patients who will benefit from surgery remains unclear and further studies including a larger population are needed to elucidate it.
CONCLUSION
In conclusion, the extent of early LV reverse remodelling after RMA is highly associated with mid-term clinical outcomes including mortality rate, heart failure events and degree of late LV reverse remodelling and repair durability in patients with non-ischaemic DCM and functional MR.
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